BTIG Reiterates Buy on Hyperfine, Maintains $2 Price Target

9/22/2026
Impact: 70
Healthcare

BTIG analyst Marie Thibault has reiterated a Buy rating on Hyperfine (NASDAQ: HYPR) and maintained a price target of $2 for the stock. This recommendation reflects confidence in the company's performance and potential growth.

AI summary, not financial advice

Share: